By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Ophthotech Corporation 

One Penn Plaza
Suite 1924
New York  New York  10119  U.S.A.
Phone: 212-845-8200 Fax: 212-845-8250


Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech's most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech's second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD, and in combination with anti-VEGF therapy in wet AMD patients.

Key Statistics

Email: n/a
Ownership: Public

Web Site: Ophthotech
Symbol: OPHT

Company News
Ophthotech (OPHT) Reports First Quarter 2017 Financial And Operating Results 5/3/2017 8:55:57 AM
Ophthotech (OPHT) To Report First Quarter 2017 Financial Results And Host Conference Call On Wednesday, May 3, 2017 4/26/2017 6:00:40 AM
Ophthotech (OPHT) Co-Founder and CEO to Step Down, CFO Named New Leader 4/25/2017 5:52:53 AM
Ophthotech (OPHT) Reports Fourth Quarter And Full Year 2016 Financial And Operating Results 2/28/2017 7:24:35 AM
Ophthotech (OPHT) To Report Fourth Quarter And Full Year 2016 Financial Results And Host Conference Call On Tuesday, February 28, 2017 2/22/2017 6:33:49 AM
Struggling to Keep Its Head Above Water: Ophthotech (OPHT) to Review Strategic Alternatives and Shake Up C-Suite 2/1/2017 6:22:57 AM
Battered Ophthotech (OPHT) Cuts 80% of Staff After Failed Clinical Trials 1/18/2017 5:51:28 AM
Ophthotech (OPHT) Clinical Disaster Spurs Massive Layoffs 12/21/2016 7:10:41 AM
Ophthotech (OPHT) Announces Results From Pivotal Phase 3 Trials Of Fovista In Wet Age-Related Macular Degeneration 12/12/2016 10:44:05 AM
Ophthotech (OPHT) Plunges as Wet AMD Drug Combo Trials With Novartis AG (NVS) Flops in Phase III Studies 12/12/2016 5:27:40 AM